It exhibited high selectivity in inhibiting the growth of KRAS-G12D-mutant cell lines and demonstrated robust efficacy against KRAS-G12D-mutant human pancreatic cancer and CRC models [80]. Here, KRAS is linked to colorectal carcinoma.